THRV-1268 Maintained a Near-Normal Ejection Fraction and Outperformed Empagliflozin Monotherapy in a Validated Model of Heart Failure; Phase 1 Studies Demonstrated Favorable Safety Profile and QTcF Shortening SAN FRANCISCO, Sept. 15, 2026 /PRNewswire/ -- Thryv Therapeutics Inc. ("Thryv"),...
Hence then, the article about thryv therapeutics announces jacc heart failure publication of converging human genetic preclinical and clinical evidence supporting phase 2a development of lead sgk1 inhibitor thrv 1268 in heart failure was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Thryv Therapeutics Announces JACC: Heart Failure Publication of Converging Human Genetic, Preclinical, and Clinical Evidence Supporting Phase 2a Development of Lead SGK1 Inhibitor THRV-1268 in Heart Failure )
Also on site :
- Drew Barrymore’s ‘Spacious’ Mirrored Medicine Cabinet Is 73% Off, and It’ll Free Up Valuable Counter Space
- 1969 CCR Rock Staple, Written in Less Than an Hour, Became One of the ‘Greatest Songs of All Time’ Without Ever Hitting No. 1
- Quote of the Day: French Writer François de La Rochefoucauld Endured Prison, Exile and a Devastating Battle Wound—Then Wrote a Piercing Truth About Giving Advice